THALES
25.1.2021 10:02:13 CET | Business Wire | Press release
NATO has selected Thales to provide the first certified defence cloud solution that can be deployed in the theatre of operations in less than 24 hours. Thales was selected after a worldwide competitive tendering process on the basis of its defence systems integration know-how. With this contract, the Group enters a new market sector and demonstrating its capacity to integrate the best civil and commercial technologies available and to adapt them to the needs of the armed forces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005006/en/
As military operations become increasingly data-driven, access to critical data and applications is a crucial requirement for the armed forces. The defence cloud developed by Thales enables the forces to analyse and share data in real time from the command centre to the theatre of operations, pursue their digital transformation in complete security, and accelerate the decision cycle to gain and maintain an operational advantage.
Until now, it could take several months and dozens of specialised engineers working at sites close to the combat zone to deploy the assets required. With Nexium Defence Cloud and its Service Design Studio and orchestration system, a small team of experts can deploy IT services and applications to locations thousands of kilometres away in just a few hours. This solution is based on a holistic approach encompassing applications management, IT, networks and security, with an overall system architecture designed to accommodate various different levels of confidentiality.
Nexium Defence Cloud incorporates the best civil and commercial technologies available to provide a complete, modular, sovereign solution that enables forces to operate fully autonomously in the theatre of operations. It offers a wide array of possible configurations, from very high-capacity and easily scalable infrastructure for command headquarters to all-in-one containerised systems that transform a forward base into a new cloud node in just a few hours.
This easy interconnection within ad hoc organisations and command structures increases mission effectiveness with an unparalleled level of security.
Nexium Defence Cloud is the most compact, highly integrated and modular solution available today. It includes all the components of military command posts (cabinets, servers, data storage media, supervision system, etc.) and meets performance requirements in terms of size, weight and power (SWaP) to simplify deployment and minimise the logistics footprint.
Through this contract, Thales once again demonstrates its system certification and standardisation know-how. Its defence cloud solution was designed to comply with the requirements of NATO's Federated Mission Networking (FMN) standard, which establishes the framework for cooperation between command-and-control networks for coalition forces. Nexium Defence Cloud has all the strengths needed to become the benchmark solution for the high-value-added deployable command posts that will be required for the coalition operations of tomorrow.
"Thales is proud to be contributing to the digital transformation of the armed forces by providing this first deployable, certified, tactical defence cloud solution. We are grateful to NATO for renewing their trust in our expertise in secure, interoperable information and communication systems." Marc Darmon , Executive Vice-President, Secure Communications and Information Systems, Thales.
About Thales
Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers – businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).
PLEASE VISIT
Thales Group
Market
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005006/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom